Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)

PURPOSE: NRG Oncology conducted a phase II trial to assess the antitumor activity and tolerability of copanlisib, a selective inhibitor of PIK3CA, in persistent or recurrent endometrial carcinoma harboring hotspot PIK3CA mutations. PATIENTS AND METHODS: Eligible patients had endometrial cancer with...

Descripción completa

Detalles Bibliográficos
Autores principales: Santin, Alessandro D., Filiaci, Virginia, Bellone, Stefania, Ratner, Elena S., Mathews, Cara A., Cantuaria, Guilherme, Gunderson, Camille C., Rutledge, Teresa, Buttin, Barbara M., Lankes, Heather A., Frumovitz, Michael, Khleif, Samir N., Huh, Warner K., Birrer, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951478/
https://www.ncbi.nlm.nih.gov/pubmed/31934607
http://dx.doi.org/10.1016/j.gore.2019.100532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951478/
https://www.ncbi.nlm.nih.gov/pubmed/31934607
http://dx.doi.org/10.1016/j.gore.2019.100532

Ejemplares similares